Mesa Verde Venture Partners, L.P. is a life sciences venture capital fund founded in San Diego in 2006.
Mesa Verde Venture Partners’ charter is to invest in a diversified portfolio of early-stage biotechnology and medical technology companies in the Southwest. Areas of focus include drug discovery/tools, medical devices and diagnostics and healthcare information technology. Mesa Verde Venture Partners is the successor fund to IngleWood Ventures of San Diego. The lead investor behind Mesa Verde Venture Partners is Sanderling Ventures.
Our preferred investment size is $250,000 to $1 million initially and up to $1.5 million per company over time. Entrepreneurs, please mail an Executive Summary to: danwood@ix.netcom.com
| Company | Date | Round | Size | Participants |
| Exagen Diagnostics | 9/12 | Venture Round | $5.3M | 5 |
| Elevation Pharmaceuticals | 1/12 | Series B | $30M | 5 |
| Elevation Pharmaceuticals | 9/11 | Series A | $17M | 4 |
| Lineagen | 1/11 | Series B | $15M | 4 |
| Lineagen | 8/10 | Series A | $10.8M | 4 |
| Elevation Pharmaceuticals | 1/10 | Series A | $30M | 4 |
| Traversa Therapeutics | 4/09 | Series B | $5M | 2 |
